S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in

Vectus Biosystems Limited (VBS.AX) Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure. Its lead compound is VB0004, which has potent anti-hypertensive properties, as well as anti-fibrotic activity in the heart and kidneys. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops AccuCal and RealCount software that improves speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was founded in 2005 and is based in Rosebery, Australia.


Overall MarketRank

0.50 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Phone61 2 9662 4144



Sales & Book Value

Annual Sales$51,186.00
Book ValueA($0.24) per share



Next Earnings DateN/A
OptionableNot Optionable

Receive VBS News and Ratings via Email

Sign-up to receive the latest news and ratings for VBS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Vectus Biosystems Limited (VBS.AX) (ASX:VBS) Frequently Asked Questions

What stocks does MarketBeat like better than Vectus Biosystems Limited (VBS.AX)?

Wall Street analysts have given Vectus Biosystems Limited (VBS.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Vectus Biosystems Limited (VBS.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Vectus Biosystems Limited (VBS.AX)'s key competitors?

Who are Vectus Biosystems Limited (VBS.AX)'s key executives?

Vectus Biosystems Limited (VBS.AX)'s management team includes the following people:
  • Dr. Karen Annette Duggan, CEO & Exec. Director
  • Mr. Robert John Waring BEc, CA, FCIS, FFin, FAICD, Company Sec.
  • Prof. Graham Jon MacDonald AM, M.D., BSc (Med), BS, FRACP, FRCP, FANZCC, Consultant

What is Vectus Biosystems Limited (VBS.AX)'s stock symbol?

Vectus Biosystems Limited (VBS.AX) trades on the ASX under the ticker symbol "VBS."

How big of a company is Vectus Biosystems Limited (VBS.AX)?

Vectus Biosystems Limited (VBS.AX) has a market capitalization of $0.00 and generates $51,186.00 in revenue each year.

What is Vectus Biosystems Limited (VBS.AX)'s official website?

The official website for Vectus Biosystems Limited (VBS.AX) is www.vectusbiosystems.com.au.

How can I contact Vectus Biosystems Limited (VBS.AX)?

The company can be reached via phone at 61 2 9662 4144.

This page was last updated on 1/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.